Identification of therapeutic targets and suitablecompounds for the treatment of Glioma by using theapproaches of NGS and Virtual Screening

Abstract

A glioma is a tumor that develops as a result of uncontrolled glial cellularmetabolism. Normally, these cells help your central nervous system function by sup-porting nerves. Although they can develop in the spinal cord, gliomas often develop inthe brain. It is believed that these primary brain tumors develop from neuroglial stemor progenitor cells. They have historically been categorised as astrocytic, oligoden-droglial, or ependymal tumors based on their histological appearance and given WHOclassifications I–IV, which denote varying degrees of aggressiveness. Gliomas comein a variety of forms, including Astrocytomas, Ependymomas, and Glioblastomas.The most dangerous type of glioma, glioblastoma is classified as grade IV glioma.when a significant fraction of the tumor cells are constantly dividing and replicating.The goal of this research is to identify therapeutic targets. Differential expressionanalysis was conducted on Microarray and RNA-seq datasets for this study. By per-forming a comparative analysis on differentially expressed genes across all datasetsused in this study, common therapeutic targets were identified. Pathway analysis wasalso carried out to identify affected pathways. Proteins with common therapeutictargets have been opted for further research. These proteins were docked with ex-isting Glioma compounds that were most often used for treatment, as well as 178FDA-approved anticancer drugs. Protein-ligand interactions were explored in orderto determine the interaction between ligands and protein.Dusteride in combination toNaldemedine and Covipatian can be used as targeted therapy for Glioma